

August 21, 2013



Resmed

ResMed Patent Infringement Case Against BMC Advances: International Trade Commission Agrees to Investigate

SAN DIEGO, Aug. 21, 2013 /PRNewswire/ -- The International Trade Commission has agreed to investigate Chinese medical device manufacturer BMC Medical Co., Ltd., and its distributors, Florida-based 3B Medical Inc. and 3B Products, L.L.C.. The Investigation was initiated at the request of ResMed (NYSE: RMD), a global innovator and pioneer in developing products for the treatment of sleep-disordered breathing and respiratory conditions. ResMed also filed suit in federal court against BMC in May, asserting patent infringement by:

- The RESmart CPAP and RESmart Auto CPAP devices, and
- The Willow nasal pillows patient interface and the iVolve nasal mask.

(Logo: <https://photos.prnewswire.com/prnh/20100203/RESMEDLOGO>)

ResMed pursued a similar legal action earlier this year against Taiwanese manufacturer APEX Medical Corp. asserting patent infringement that resulted in APEX consenting to an order barring infringing products from the U.S. market.

"We're encouraged by the ITC's action to investigate this case against BMC," said ResMed Global General Counsel and Chief Administrative Officer David Pendarvis. "For more than two decades, ResMed has generated significant advances in innovative products for sleep-disordered breathing therapy. We invest over \$100 million in research and development each year to fuel these advances and other companies should not be allowed to infringe ResMed's intellectual property by using our technology."

About ResMed:

ResMed is a global leader in the development, manufacturing and marketing of medical products for the diagnosis, treatment and management of respiratory disorders, with a focus on sleep-disordered breathing. The company is dedicated to developing innovative products to improve the lives of those who suffer from these conditions and to increasing awareness among patients and healthcare professionals of the potentially serious health consequences of untreated sleep-disordered breathing. For more information on ResMed, visit www.resmed.com.

Contacts:

For News Media

Gretchen Griswold

Director, Global Corporate Communications

O: 858-836-6789

news@resmed.com

**For the Finance and Investor
Community**

Constance Bienfait

Director, Investor Relations

O: 858-836-5971

constance.bienfait@resmed.com

SOURCE ResMed Inc.